Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5615417 | Journal of Clinical Lipidology | 2016 | 19 Pages |
Abstract
LA for severe FH can be delivered effectively in the short term in developing nations, but costs are a major barrier to sustaining this mode of treatment for this high-risk group of patients. New drug therapies for FH, such as the proprotein convertase subtilisin/kexin type 9 inhibitors, microsomal triglyceride transfer protein inhibitors, and apolipoprotein-B100 antisense oligonucleotides may allow improved care for these patients, but costs and long-term safety remain as issues to be addressed.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Kah Lin MD, FRCP, FACC, FESC, FCCP, Michael M. BPharm, MBBS(Hons), Yin Mei MBBS, FAMM, FRCP, Joep C. PhD, Gerald F. DSc, MD, PhD, FRCP, FRACP,